How much funding has Capstan Therapeutics raised?

Capstan Therapeutics has raised $340.0M in total funding, most recently a Series B round.

Who are Capstan Therapeutics's investors?

Capstan Therapeutics's investors include AbbVie Ventures, Pfizer Ventures, Novartis Venture Fund, Polaris Partners, Forbion Capital Partners, Mubadala Investment Company.

When was Capstan Therapeutics founded?

Capstan Therapeutics was founded in 2021.

Where is Capstan Therapeutics headquartered?

Capstan Therapeutics is headquartered in San Diego, United States.

What industry is Capstan Therapeutics in?

Capstan Therapeutics operates in Biotech, Healthcare, Pharmaceutical.

How many employees does Capstan Therapeutics have?

Capstan Therapeutics has 51-200 employees.

Capstan Therapeutics

Closed

In vivo engineering of cells through targeted lipid nanoparticles.

San Diego, United States · Founded 2021 · $340.0M raised

Biotech

Healthcare

Pharmaceutical

Headquarters: San Diego
Employees: 51–200
Founded: 2021
Business Model: B2B

Website: abbvie.com
Total Funding: $340.0M
Last Round: $175.0M Series BMar 2024
Rounds: 3

About

Capstan Therapeutics is a San Diego-based biotechnology company founded in 2021 as a Penn spinout. The company developed in vivo CAR-T cell therapies using targeted lipid nanoparticles (CellSeeker™ LNPs) to engineer T cells inside the body for treating autoimmune diseases and cancer. Capstan was acquired by AbbVie in 2025 for $2.1 billion upfront.

Summary

Capstan Therapeutics is a Biotech company based in San Diego, United States, founded in 2021. It has raised $340.0M in total across 3 rounds, most recently a $175.0M Series B round in Mar 2024. Investors include AbbVie Ventures, Pfizer Ventures and Novartis Venture Fund.

LinkedIn X (Twitter)